Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 19;23(1):e0096.
doi: 10.1097/CLD.0000000000000096. eCollection 2024 Jan-Jun.

Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity

Gres Karim  1 , Megha Reddy  2 , Navim Mobin  1 , Ilan Weisberg  1 , Amreen Dinani  3
Affiliations

Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity

Gres Karim et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ilan Weisberg is on the speakers’ bureau for Gilead. Amreen Dinani consults for Guidepoint and Kinetix. The remaining authors have no conflicts to report.

Figures

None
Graphical abstract
FIGURE 1
FIGURE 1
Proposed summative algorithm for the treatment of IRH. A proposed summative algorithm for the treatment of IRH. Abbreviations: ICI: immune checkpoint inhibitor; IRH, immune checkpoint inhibitor-related hepatotoxicity.
FIGURE 2
FIGURE 2
Proposed summative algorithm for the treatment of steroid-refractory IRH. A proposed algorithm for the management of steroid-refractory IRH when liver chemistries worsen or with ineffective steroid tapering. Abbreviations: UDCA: ursodeoxycholic acid; IRH: immune checkpoint inhibitor-related hepatotoxicity.
See this image and copyright information in PMC

References

    1. Brahmer JR, Lacchetti C, Schneider BJ, et al. . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–1768. - PMC - PubMed
    1. De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2:100170. - PMC - PubMed
    1. Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol. 2021;27:5376–5391. - PMC - PubMed
    1. Bessone F, Bjornsson ES. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. World J Hepatol. 2022;14:1269–1276. - PMC - PubMed
    1. Xing H, Wang Y, Qu B, Wei Q, Li C, Pan C, et al. . The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Transl Oncol. 2023;28:101619. - PMC - PubMed